Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke.
Issue Date
2017-12-08Keywords
COGNITIVE IMPAIRMENTMEDICATION MANAGEMENT
Local subject classification
STROKE
Metadata
Show full item recordCitation
Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke. 2017, 12 (12):e0189339 PLoS ONEPublisher
PLoS ONEJournal
PloS oneDOI
10.1371/journal.pone.0189339PubMed ID
29220386Abstract
While medication adherence is essential for the secondary prevention of stroke, it is often sub-optimal, and can be compromised by cognitive impairment. This study aimed to systematically review and meta-analyse the association between cognitive impairment and medication non-adherence in stroke.A systematic literature search of longitudinal and cross-sectional studies of adults with any stroke type, which reported on the association between any measure of non-adherence and cognitive impairment, was carried out according to PRISMA guidelines. Odds ratios and 95% confidence intervals were the primary measure of effect. Risk of bias was assessed using the Cochrane Bias Methods Group's Tool to Assess Risk of Bias in Cohort Studies, with evidence quality assessed according to the GRADE approach. We conducted sensitivity analyses according to measure of cognitive impairment, measure of medication adherence, population, risk of bias and adjustment for covariates. The protocol was registered with PROSPERO.
From 1,760 titles and abstracts, we identified 9 studies for inclusion. Measures of cognitive impairment varied from dementia diagnosis to standardised cognitive assessments. Medication adherence was assessed through self-report or administrative databases. The majority of studies were of medium risk of bias (n = 6); two studies had low risk of bias. Findings were mixed; when all studies were pooled, there was no evidence of an association between cognitive impairment and medication non-adherence post-stroke [OR (95% CI): 0.85 (0.66, 1.03)]. However, heterogeneity was substantial [I2 = 90.9%, p < .001], and the overall evidence quality was low.
Few studies have explored associations between cognitive impairment and medication adherence post-stroke, with substantial heterogeneity in study populations, and definitions and assessments of non-adherence and cognitive impairment. Further research using clear, standardised and objective assessments is needed to clarify the association between cognitive impairment and medication non-adherence in stroke.
Item Type
ArticleLanguage
enISSN
1932-6203ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0189339
Scopus Count
Collections
Related articles
- Pharmacotherapy for chronic cognitive impairment in traumatic brain injury.
- Authors: Dougall D, Poole N, Agrawal N
- Issue date: 2015 Dec 1
- Multimodal Interventions to Enhance Adherence to Secondary Preventive Medication after Stroke: A Systematic Review and Meta-Analyses.
- Authors: Al AlShaikh S, Quinn T, Dunn W, Walters M, Dawson J
- Issue date: 2016 Apr
- Adherence to medication in patients with dementia: predictors and strategies for improvement.
- Authors: Arlt S, Lindner R, Rösler A, von Renteln-Kruse W
- Issue date: 2008
- A systematic review of medication non-adherence in persons with dementia or cognitive impairment.
- Authors: Smith D, Lovell J, Weller C, Kennedy B, Winbolt M, Young C, Ibrahim J
- Issue date: 2017
- Cognitive impairment and medication adherence post-stroke: A five-year follow-up of the ASPIRE-S cohort.
- Authors: Rohde D, Gaynor E, Large M, Mellon L, Bennett K, Williams DJ, Brewer L, Hall P, Callaly E, Dolan E, Hickey A
- Issue date: 2019